Celltrion Healthcare (Kosdaq:091990), the marketing and distribution arm of South Korean biopharmaceutical company Celltrion (KRX:068270), has signed supply deals for its monoclonal antibody to treat COVID-19 with nine European countries, Reuters news agency reported on Tuesday.
Earlier this month, the European Commission had approved Celltrion's antibody therapy Regkirona, granting marketing authorisation for adults with COVID-19 who are at increased risk of progressing to a severe condition.
In a statement, the company said that the first batch of 50,000 doses will be shipped to Europe this year adding that it in talks with 47 other nations including in Asia, Central and South America and the Middle East.
The company's antibody treatment was initially approved in South Korea and has been administered to around 25,000 local COVID-19 patients as of last week, Reuters added.
AbbVie's ELAHERE receives full US FDA approval
Johnson & Johnson's OPSYNVI receives US FDA approval
Outlook Therapeutics receives positive CHMP opinion for ONS-5010 in wet AMD treatment
Human Immunology Biosciences receives ODD from FDA for felzartamab
Eton Pharmaceuticals acquires PKU GOLIKE, expanding rare disease portfolio
Vertex receives FDA clearance for VX-407 Investigational New Drug Application for ADPKD
Phanes Therapeutics receives FDA Fast Track designation for PT886
Bio-Thera Solutions signs new licensing agreement with SteinCares
FDA accepts resubmission of Citius Pharmaceuticals, Inc's BLA for LYMPHIR
GSK Plc reports positive Phase III Jemperli data for endometrial cancer
ImmVira receives FDA Fast Track designation for MVR-T3011 IT